Evidence map›Paper›PMID 37147383›Full record

ArticleScientific reports2023

Effects of rIL2/anti-IL2 antibody complex on chikungunya virus-induced chronic arthritis in a mouse model.

Sarah R Tritsch, Abigail J Porzucek, Arnold M Schwartz, Abigale M Proctor, Richard L Amdur, Patricia S Latham, Gary L Simon, Christopher N Mores, Aileen Y Chang

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
0.6field-weighted citation impact, top 32% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 2 citations in OpenAlex.

  1. Article
  2. Review
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

Sarah R TritschMilken Institute School of Public Health, The George Washington University, Washington, D.C., USA. sarahtritsch@gwu.edu.ORCID 0000-0002-8132-0801
Abigail J PorzucekMilken Institute School of Public Health, The George Washington University, Washington, D.C., USA.
Arnold M SchwartzSchool of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Abigale M ProctorMilken Institute School of Public Health, The George Washington University, Washington, D.C., USA.
Richard L AmdurSchool of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Patricia S LathamSchool of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.ORCID 0000-0003-2782-9444
Gary L SimonSchool of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA.
Christopher N MoresMilken Institute School of Public Health, The George Washington University, Washington, D.C., USA.
Aileen Y ChangSchool of Medicine and Health Sciences, The George Washington University, Washington, D.C., USA. chang@gwu.edu.
George Washington University · USMilken Institute · US

Funding

The role of IL-2 therapy for Relapsing-Remitting Chikungunya ArthritisK23AR076505 · NIAMS · GEORGE WASHINGTON UNIVERSITY · PI CHANG, AILEEN · 2020 to 2022
$466k
NIAMS NIH HHS K23 AR076505
6 · The paper itself

Abstract

Chikungunya virus (CHIKV) is characterized by disabling joint pain that can cause persistent arthritis in approximately one-fourth of patients. Currently, no standard treatments are available for chronic CHIKV arthritis. Our preliminary data suggest that decreases in interleukin-2 (IL2) levels and regulatory T cell (Treg) function may play a role in CHIKV arthritis pathogenesis. Low-dose IL2-based therapies for autoimmune diseases have been shown to up-regulate Tregs, and complexing IL2 with anti-IL2 antibodies can prolong the half-life of IL2. A mouse model for post-CHIKV arthritis was used to test the effects of recombinant IL2 (rIL2), an anti-IL2 monoclonal antibody (mAb), and the complex on tarsal joint inflammation, peripheral IL2 levels, Tregs, CD4 + effector T cells (Teff), and histological disease scoring. The complex treatment resulted in the highest levels of IL2 and Tregs, but also increased Teffs, and therefore did not significantly reduce inflammation or disease scores. However, the antibody group, which had moderately increased levels of IL2 and activated Tregs, resulted in a decreased average disease score. These results suggest the rIL2/anti-IL2 complex stimulates both Tregs and Teffs in post-CHIKV arthritis, while the anti-IL2 mAb increases IL2 availability enough to shift the immune environment towards a tolerogenic one.

Indexed as

ArthritisChikungunya FeverChikungunya virusAnimalsDisease Models, AnimalInflammationInterleukin-2MiceT-Lymphocytes, RegulatoryInterleukin-2

Identifiers

PMID37147383
PMCPMC10163023
OpenAlexW4372337176

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.